178 related articles for article (PubMed ID: 37162517)
1. Clinical significance of plasma PD-L1
Xu P; Liu J; Chen H; Shang L; Wang F; Zhu Y; Guo Y; Li F; Yan F; Xie X; Li L; Gu W; Lin Y
Ann Hematol; 2023 Sep; 102(9):2435-2444. PubMed ID: 37162517
[TBL] [Abstract][Full Text] [Related]
2. Comparison of PD-L1 detection assays and corresponding significance in evaluation of diffuse large B-cell lymphoma.
Huang S; Nong L; Liang L; Zheng Y; Wang W; Liu J; Li D; Li X; Wang Y; Zhang B; Li T
Cancer Med; 2019 Jul; 8(8):3831-3845. PubMed ID: 31150165
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma.
Ishikawa E; Nakamura M; Shimada K; Tanaka T; Satou A; Kohno K; Sakakibara A; Furukawa K; Yamamura T; Miyahara R; Nakamura S; Kato S; Fujishiro M
J Gastroenterol; 2020 Jan; 55(1):39-50. PubMed ID: 31493237
[TBL] [Abstract][Full Text] [Related]
4. Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas.
Liu Y; Ma J; Yu K; Li M; Liu F; Yan Q; Wang Z; Guo S
Pathol Res Pract; 2018 Apr; 214(4):507-512. PubMed ID: 29598887
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy.
Smith SD; Till BG; Shadman MS; Lynch RC; Cowan AJ; Wu QV; Voutsinas J; Rasmussen HA; Blue K; Ujjani CS; Shustov A; Cassaday RD; Fromm JR; Gopal AK
Br J Haematol; 2020 Jun; 189(6):1119-1126. PubMed ID: 32030732
[TBL] [Abstract][Full Text] [Related]
6. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
[TBL] [Abstract][Full Text] [Related]
7. Expression of PD-L1 and YWHAZ in Patients with Diffuse Large B Cell Lymphoma: A Possible Association with the Prognosis of Lymphoma.
Yan S; Shang Q; Fan Z; Yang Y; Liu Y; Gao H; Chen K; Liang F; Li X; Zhang Q; Yan H
J Immunol Res; 2022; 2022():5633096. PubMed ID: 36213322
[TBL] [Abstract][Full Text] [Related]
8. The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma.
Feng Y; Feng X; Jing C; Yu X; Zheng Y; Xu C
Sci Rep; 2022 Jan; 12(1):36. PubMed ID: 34996890
[TBL] [Abstract][Full Text] [Related]
9. The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis.
Qiu L; Zheng H; Zhao X
BMC Cancer; 2019 Mar; 19(1):273. PubMed ID: 30917792
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications.
Xing W; Dresser K; Zhang R; Evens AM; Yu H; Woda BA; Chen BJ
Oncotarget; 2016 Sep; 7(37):59976-59986. PubMed ID: 27527850
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
Xie M; Huang X; Ye X; Qian W
Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
[TBL] [Abstract][Full Text] [Related]
12. Programmed death ligand 1 expression in diffuse large B cell lymphoma: correlation with clinicopathological prognostic factors.
Ibrahim EM; Refat S; El-Ashwah S; Fahmi MW; Ibrahiem AT
J Egypt Natl Canc Inst; 2023 May; 35(1):12. PubMed ID: 37150782
[TBL] [Abstract][Full Text] [Related]
13. The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma.
Fang X; Xiu B; Yang Z; Qiu W; Zhang L; Zhang S; Wu Y; Zhu X; Chen X; Xie S; Yi X; Liang A; Zeng Y
Medicine (Baltimore); 2017 Apr; 96(15):e6398. PubMed ID: 28403071
[TBL] [Abstract][Full Text] [Related]
14. Programmed death-ligand 1 expression in diffuse large B-cell lymphoma is associated with poor prognosis.
Al-Khateeb E; Abbas MA; Khader MB; Sughayer MA
Int J Biol Markers; 2023 Mar; 38(1):53-60. PubMed ID: 36617986
[TBL] [Abstract][Full Text] [Related]
15. PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program.
Li L; Sun R; Miao Y; Tran T; Adams L; Roscoe N; Xu B; Manyam GC; Tan X; Zhang H; Xiao M; Tzankov A; Visco C; Dybkaer K; Bhagat G; Tam W; Hsi ED; van Krieken JH; You H; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; Zhang M; Winter JN; Medeiros LJ; Rassidakis GZ; Vaupel CA; Li Y; Dakappagari N; Xu-Monette ZY; Young KH
Mod Pathol; 2019 Jun; 32(6):741-754. PubMed ID: 30666052
[TBL] [Abstract][Full Text] [Related]
16. Clinical Significance of PD-L1
Theodoraki MN; Yerneni SS; Hoffmann TK; Gooding WE; Whiteside TL
Clin Cancer Res; 2018 Feb; 24(4):896-905. PubMed ID: 29233903
[TBL] [Abstract][Full Text] [Related]
17. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial.
Rossille D; Gressier M; Damotte D; Maucort-Boulch D; Pangault C; Semana G; Le Gouill S; Haioun C; Tarte K; Lamy T; Milpied N; Fest T; ;
Leukemia; 2014 Dec; 28(12):2367-75. PubMed ID: 24732592
[TBL] [Abstract][Full Text] [Related]
18. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.
Dong L; Lv H; Li W; Song Z; Li L; Zhou S; Qiu L; Qian Z; Liu X; Feng L; Meng B; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X; Zhang H
Oncotarget; 2016 May; 7(22):33350-62. PubMed ID: 27147575
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of PD-1 and PD-L1 molecules in patients with diffuse large B-cell lymphoma, not otherwise specified: Correlation with clinical and pathological findings.
Karakatsanis S; S Papadatos S; Syrigos N; Marinos L; Pouliou E; Papanikolaou A
J BUON; 2021; 26(2):569-579. PubMed ID: 34077007
[TBL] [Abstract][Full Text] [Related]
20. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.
Kiyasu J; Miyoshi H; Hirata A; Arakawa F; Ichikawa A; Niino D; Sugita Y; Yufu Y; Choi I; Abe Y; Uike N; Nagafuji K; Okamura T; Akashi K; Takayanagi R; Shiratsuchi M; Ohshima K
Blood; 2015 Nov; 126(19):2193-201. PubMed ID: 26239088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
